Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OXTR | P30559 | 2/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308698 | 0.94 | FAP (0.36) | FAPNAA50KEAP1OPRM1OPRD1 | |
| SCHEMBL22018362 | 0.90 | FAP (0.38) | FAPNAA50KEAP1OXTRTERT | |
| SCHEMBL23871517 | 0.89 | FAP (0.38) | FAPNAA50KEAP1OXTRTERT | |
| SCHEMBL26391856 | 0.86 | APLNR (0.38) | FAPNAA50KEAP1OXTRKDM1A | |
| SCHEMBL22019147 | 0.85 | FAP (0.33) | FAPNAA50OPRM1OPRD1OXTR | |
| SCHEMBL29308258 | 0.85 | CTSD (0.34) | FAPNAA50KEAP1OXTRTERT | |
| SCHEMBL29308497 | 0.84 | FAP (0.36) | FAPNAA50KEAP1OXTRTERT | |
| SCHEMBL29308274 | 0.84 | MAPK8 (0.34) | FAPNAA50KEAP1OXTRTERT | |
| SCHEMBL22922802 | 0.82 | NAA50 (0.42) | NAA50KEAP1OXTRKDM1AAPLNR | |
| SCHEMBL29308489 | 0.82 | NAA50 (0.39) | FAPNAA50KEAP1OXTRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | FAP 1121/4885NAA50 3702/4885KEAP1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.